ArrowMark Colorado Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-20,556	Closed	-$464K	–	291
2014 Q2	$464K	Hold	20,556	–	–	0.01%	259
2014 Q1	$500K	Sell	20,556 -7,944	-28%	-$201K	0.02%	242
2013 Q4	$712K	Buy	28,500 +17	+0.1%	+$401	0.02%	216
2013 Q3	$782K	Buy	28,483 +4,781	+20%	+$99.9K	0.03%	210
2013 Q2	$430K	Buy	+23,702	New	+$326K	0.12%	88

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ArrowMark Colorado Holdings's ACAD Position: Q3 2014 in Review

ArrowMark Colorado Holdings sold out of Acadia Pharmaceuticals (ACAD) in Q3 2014, closing a stake of 20,556 shares — an estimated $464K sold.

ArrowMark Colorado Holdings first reported a position in ACAD in Q2 2013 and held it in 5 quarters. The position peaked at $782K in Q3 2013. 162 funds tracked by Wall St. Rank hold ACAD as of Q3 2014.

ArrowMark Colorado Holdings reported no remaining Acadia Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
ArrowMark Colorado Holdings sold 20,556 Acadia Pharmaceuticals shares in Q3 2014, an estimated $464K.
ArrowMark Colorado Holdings first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 5 quarters.
ArrowMark Colorado Holdings's Acadia Pharmaceuticals position peaked at $782K in Q3 2013.
162 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2014.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2014, filed 14 Nov 2014.